Wellington Management Group LLP Reduces Stake in Prestige Consumer Healthcare Inc. $PBH

Wellington Management Group LLP lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,460 shares of the company’s stock after selling 1,144 shares during the period. Wellington Management Group LLP’s holdings in Prestige Consumer Healthcare were worth $1,845,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new stake in Prestige Consumer Healthcare in the first quarter valued at approximately $38,000. McIlrath & Eck LLC boosted its position in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Costello Asset Management INC purchased a new stake in Prestige Consumer Healthcare in the 1st quarter worth approximately $112,000. GAMMA Investing LLC boosted its position in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock worth $162,000 after purchasing an additional 496 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Prestige Consumer Healthcare by 97.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,925 shares of the company’s stock worth $150,000 after purchasing an additional 950 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Up 1.3%

Shares of PBH stock opened at $68.11 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The company has a market cap of $3.35 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 2.15 and a beta of 0.43. The stock has a 50 day simple moving average of $73.63 and a 200-day simple moving average of $80.55. Prestige Consumer Healthcare Inc. has a 1-year low of $62.95 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company’s quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Canaccord Genuity Group lowered their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.